Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.54 |
| ▸ | SI | P14410 | 1/20 | 0.54 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617817 | 0.96 | GAA (0.54) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL434421 | 0.94 | MGAM (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL1014646 | 0.92 | GAA (0.58) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL20599697 | 0.90 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL6890748 | 0.83 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL2680543 | 0.83 | GAA (0.51) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13848940 | 0.83 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10236626 | 0.83 | GAA (0.51) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL4997648 | 0.83 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL771683 | 0.83 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709480-A1 | 5,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | Amgen Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4642785-A1 | IL-17A MODULATORS | Usynova Pharmaceuticals Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025087274-A1 | AZABICYCLO DERIVATIVE AND PREPARATION METHOD THEREFOR, AND USE | 浙江海正药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| US-20250084087-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-03-13 | — | — | US | disclosed |
| WO-2025042730-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024138286-A1 | IL-17A MODULATORS | USYNOVA PHARMACEUTICALS, LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024139171-A1 | IL-17A MODULATORS | USYNOVA PHARMACEUTICALS, LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| EP-1509225-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003099275-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2003-12-04 | — | — | WO | disclosed |
| CN-1109675-C | Aryl pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2003-05-28 | — | — | CN | disclosed |
| US-5958934-A | 5-HT 2B ANTAGONIST | SYNTEX (U.S.A.) INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5952331-A | SELECTIVE 5HT2B ANTAGONISTS; SEROTONIN RECEPTOR ANTAGONIST; TREATING DISORDERS OF THE GASTROINTESTINAL TRACK, RESTENOSIS, ASTHMA AND OBSTRUCTIVE AIRWAY DISEASE, PROSTATIC HYPERPLASIA, GENERALIZED ANXIETY, PANIC DISORDER | SYNTEX (USA) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| CN-1223641-A | Aryl pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 1999-07-21 | — | — | CN | disclosed |
| EP-0901474-A1 | ARYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
| US-5863924-A | Aryl pyrimidine derivatives | SYNTEX (U.S.A.) INC. (US) | 1999-01-26 | — | — | US | disclosed |
| WO-1997044326-A1 | ARYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | GAA 290/4885MGAM 863/4885SI 1984/4885 |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | HAVCR2, HCCS, ZC3HAV1 | GAA 4301/4885MGAM 4346/4885SI 2467/4885 |
| US-20250084087-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | GAA 2786/4885MGAM 3466/4885SI 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.